Altamira Therapeutics Issues Shareholder Letter

Highlights Company's progress to becoming a pure-play RNA business and tech strategy and penetrate the multi-billion TAM

HAMILTON, BERMUDA / ACCESSWIRE / May 18, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today issued a Letter to Shareholders providing highlights of the Company's recent achievements and its 2022 outlook.

Company highlights include:

• Altamira's pivot toward becoming a pure-play RNA therapeutics company
• The progress of its RNA business and tech strategy to penetrate the multi-billion total addressable market (TAM) $50 billion TAM
• The strategy with its RNA AM-401 program to achieve its first clinical proof of concept targeting KRAS driven cancers
• The rapid global expansion and commercialization of its drug-free nasal spray Bentrio
• Timeline of anticipated readouts of several ongoing Bentrio clinical trials
• Upcoming clinical data from its AM-125 nasal spray drug program for vertigo
• Upcoming regulatory milestones

"Over the last several months we've made tremendous strides in pivoting our business towards an RNA therapeutics pure play," said Thomas Meyer, Altamira's founder, CEO and Chairman. "We've laid the foundation by developing our proprietary OligoPhore^TM / SemaPhore^TM platforms for extrahepatic RNA delivery and are progressing the preclinical development of our AM-401 for treatment of KRAS-driven cancers.

Concurrent with our business transition, we have continued to invest in our non-RNA legacy programs and to drive the toward several important milestones. Our drug-free nasal spray Bentrio continues to expand its global commercialization footprint in over 20 countries while we advance three clinical trials. Based on positive interim clinical data for our AM-125 nasal spray drug for vertigo, we look forward to the upcoming read-out from our Phase 2 clinical trial . We plan to divest or spin off all legacy assets by year-end 2022 to more fully realize their value and become a pure play RNA company."

To read the shareholder letter, please visit: https://ir.altamiratherapeutics.com/

About Altamira Therapeutics

Altamira Therapeutics (NASDAQ: CYTO) is dedicated to developing therapeutics that address important unmet medical needs. The Company is currently active in three areas: the development of RNA therapeutics for extrahepatic therapeutic targets (OligoPhore™ / SemaPhore™ platforms; preclinical), nasal sprays for protection against airborne viruses and allergens (Bentrio; commercial) or the treatment of vertigo (AM-125; Phase 2), and the development of therapeutics for intratympanic treatment of tinnitus or hearing loss (Keyzilen® and Sonsuvi®, Phase 3). Founded in 2003, Altamira is headquartered in Hamilton, Bermuda, with its main operations in Basel, Switzerland. For more information, visit: https://altamiratherapeutics.com.